Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neoplasms by Histologic Type 2Neoplasms 2Myeloproliferative Disorders 2Leukemia, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Hematologic Diseases 2Bone Marrow Diseases 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Myeloid, Chronic-Phase 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

Rituximab 2Epoetin Alfa 2Early Intervention, Educational 2Dexamethasone 2Darbepoetin alfa 2Bortezomib 2ponatinib 1pegaspargase 1isatuximab 1ibrutinib 1ibritumomab tiuxetan 1ferrous sulfate 1ferric gluconate 1ferric carboxymaltose 1cirmtuzumab 1blinatumomab 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Vorinostat 1Vincristine 1Sucrose 1Prednisone 1Methotrexate 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1Ifosfamide 1Etoposide 1Doxorubicin 1Daunorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoproliferative Disorders × ponatinib × Clear all
NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡